SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Piroth Z)
 

Sökning: WFRF:(Piroth Z) > Fractional flow res...

Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial

Smits, P. C. (författare)
Laforgia, P. L. (författare)
Abdel-Wahab, M. (författare)
visa fler...
Neumann, F. J. (författare)
Richardt, G. (författare)
Boxma-de Klerk, B. (författare)
Lunde, K. (författare)
Schotborgh, C. E. (författare)
Piroth, Z. (författare)
Horak, D. (författare)
Wlodarczak, A. (författare)
Frederix, G. W. (författare)
Omerovic, Elmir, 1968 (författare)
Gothenburg University,Göteborgs universitet,Center for Cardiovascular and Metabolic Research (CMR)
visa färre...
 (creator_code:org_t)
Europa Digital & Publishing, 2020
2020
Engelska.
Ingår i: Eurointervention. - : Europa Digital & Publishing. - 1774-024X. ; 16:3, s. 225-232
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: The Compare-Acute trial showed superiority of fractional flow reserve (FFR)-guided acute complete revascularisation compared to culprit-only treatment in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD) at one year. The aim of this study was to investigate the outcome at three years, together with cost analysis of this strategy. Methods and results: After primary percutaneous coronary intervention (PCI), 885 patients with STEMI and MVD were randomised (1:2 ratio) to FFR-guided complete revascularisation (295 patients) or infarct-related artery (IRA)-only treatment (590 patients). After 36 months, the primary endpoint (composite of death, myocardial infarction, revascularisation, stroke) occurred significantly less frequently in the FFR-guided complete revascularisation group: 46/295 patients (15.6%) versus 178/590 patients (30.2%) (HR 0.46, 95% CI: 0.33-0.64; p<0.001). This benefit was driven mainly by the reduction of revascularisations in the follow-up (12.5% vs 25.2%; HR 0.45, 95% CI: 0.31-0.64; p<0.001). Cost analysis shows benefit of the FFR-guided complete revascularisation strategy, which can reduce the cost per patient by up to 21% at one year (8,150(sic) vs 10,319(sic)) and by 22% at three years (8,653(sic) vs 11,100(sic)). Conclusions: In patients with STEMI and MVD, FFR-guided complete revascularisation is more beneficial in terms of outcome and healthcare costs compared to IRA-only revascularisation at 36 months.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

clinical trials
fractional flow reserve
multiple vessel disease
STEMI
percutaneous coronary intervention
st-segment elevation
randomized-trial
revascularization
disease
lesion
Cardiovascular System & Cardiology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy